Cirmtuzumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized |
Target | ROR1 |
Clinical data | |
Other names | UC-961 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]
References
- ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. (2015). "Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts". Blood. 126 (23): 1736. doi:10.1182/blood.V126.23.1736.1736.
- ^ "Researchers to test novel drug combination against toughest breast cancers". Medical Express. 2018-08-27.
- ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ "1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo". Lymphoma News Today. 2018-05-18.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Monoclonal antibodies for tumors
- All stub articles
- Antineoplastic and immunomodulating drug stubs